Substantial decrease of PFAS with anion exchange resin treatment – A clinical cross-over trial

Janne Julie Møller, Ann Christine Lyngberg, Paula Edeusa Christina Hammer, Esben Meulengracht Flachs, Ole Steen Mortensen, Tina Kold Jensen, Gesche Jürgens, Axel Andersson, Anne Merete Boas Soja, Morten Lindhardt*


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

1 Downloads (Pure)


Background: Per- and polyfluoroalkyl substances (PFAS) are heat and stain resisting chemicals. They are persistent, bioaccumulating and spread ubiquitously. Many hotspots where humans are exposed to high levels of PFAS have been reported. A few small observational studies in humans suggest that treatment with an Anion Exchange Resin (AER) decreases serum PFAS. This first clinical controlled crossover study aimed to assess whether AER decreases perfluorooctanesulfonic acid (PFOS) in highly exposed adults. Methods: An open label 1:1 randomized treatment sequence crossover study with allocation to oral AER (cholestyramine 4 g three times daily) or observation for 12 weeks was conducted among citizens from a PFAS hotspot. Main inclusion criteria was serum PFOS > 21 ng/mL. Primary endpoint was change in serum PFOS levels between treatment and observational period. Results: In total, 45 participants were included with a mean age of 50 years (SD 13). Serum PFOS baseline median was 191 ng/mL (IQR: 129–229) and decreased with a mean of 115 ng/mL (95 % CI: 89–140) on treatment, and 4.3 ng/mL in observation period corresponding to a decrease of 60 % (95 % CI: 53–67; p < 0.0001). PFHxS, PFOA, PFNA and PFDA decreased during treatment between 15 and 44 %. No serious adverse events were reported. Conclusions: Oral treatment with AER significantly lowered serum PFOS concentrations suggesting a possible treatment for enhancing elimination of PFOS in highly exposed adults.

TidsskriftEnvironment International
Antal sider7
StatusUdgivet - mar. 2024


Dyk ned i forskningsemnerne om 'Substantial decrease of PFAS with anion exchange resin treatment – A clinical cross-over trial'. Sammen danner de et unikt fingeraftryk.